Skip to content

Press Releases

May 02, 2018
Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bempedoic Acid
— Met Primary Endpoint of Safety and Tolerability in Largest and Longest Duration  Study — — Bempedoic Acid Achieved Additional 20% On-Treatment LDL-C Lowering on Background Maximally Tolerated Statin Therapy —  — Additional hsCRP Reduction of 22% on Background Maximally Tolerated Statin Therapy —
Apr 13, 2018
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., April 13, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Mar 27, 2018
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia
— Study Met Primary Endpoint with 30% Additional LDL-C Lowering — — hsCRP Reduction of 34% — — Observed to be Safe and Well-Tolerated in This Study — — Conference Call and Webcast on Tuesday, March 27, 2018, at 8:30 a.m. Eastern Daylight Time — ANN ARBOR, Mich., March 27, 2018 (GLOBE NEWSWIRE) --
Mar 07, 2018
Esperion to Participate in Fireside Chat at March 2018 Investor Conferences
ANN ARBOR, Mich., March 07, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Mar 07, 2018
Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid
— Study 4 Met Primary Endpoint with 28% Additional LDL-C Lowering on Background Ezetimibe and Up to the Lowest Daily Dose of a Statin — — hsCRP Reduction of 33% — — Observed to be Safe and Well-Tolerated in This Study — — Conference Call and Webcast on Wednesday, March 7, 2018, at 8:30 a.m.
Feb 23, 2018
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Feb 20, 2018
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results
ANN ARBOR, Mich., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Jan 03, 2018
Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference
Fireside Chat Webcast on Wednesday, January 10, 2018 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time ANN ARBOR, Mich., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,